Scaling up Xpert MTB/RIF technology: the costs of laboratory‐ vs. clinic‐based roll‐out in South Africa
Open Access
- 12 June 2012
- journal article
- Published by Wiley in Tropical Medicine & International Health
- Vol. 17 (9), 1142-1151
- https://doi.org/10.1111/j.1365-3156.2012.03028.x
Abstract
Objective The World Health Organization recommends using Xpert MTB/RIF for diagnosis of pulmonary tuberculosis (PTB), but there is little evidence on the optimal placement of Xpert instruments in public health systems. We used recent South African data to compare the cost of placing Xpert at points of TB treatment (all primary clinics and hospitals) with the cost of placement at sub-district laboratories. Methods We estimated Xpert’s cost/test in a primary clinic pilot and in the pilot phase of the national Xpert roll-out to smear microscopy laboratories; the expected future volumes for each of 223 laboratories or 3799 points of treatment; the number and cost of Xpert instruments required and the national cost of using Xpert for PTB diagnosis for each placement scenario in 2014. Results In 2014, South Africa will test 2.6 million TB suspects. Laboratory placement requires 274 Xpert instruments, while point-of-treatment placement requires 4020 instruments. With an Xpert cartridge price of $14.00, the cost/test is $26.54 for laboratory placement and $38.91 for point-of-treatment placement. Low test volumes and a high number of sites are the major contributors to higher point-of-treatment costs. National placement of Xpert at laboratories would cost $71 million/year; point-of-treatment placement would cost $107 million/year, 51% more. Conclusion Placing Xpert technology at points of treatment is substantially more expensive than placing the instruments in smear microscopy laboratories. The incremental benefits of point-of-treatment placement, in terms of better patient outcomes, will have to be equally substantial to justify the additional cost to the national health budget.Keywords
This publication has 17 references indexed in Scilit:
- Location of Xpert® MTB/RIF in centralised laboratories in South Africa undermines potential impact.The International Journal of Tuberculosis and Lung Disease, 2012
- Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?The International Journal of Tuberculosis and Lung Disease, 2011
- Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness AnalysisPLoS Medicine, 2011
- Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective StudyPLoS Medicine, 2011
- Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive studyThe Lancet Infectious Diseases, 2011
- Xpert MTB/RIF: a New Pillar in Diagnosis of Extrapulmonary Tuberculosis?Journal of Clinical Microbiology, 2011
- Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation studyThe Lancet, 2011
- Xpert TB diagnostic highlights gap in point-of-care pipeline.The Lancet Infectious Diseases, 2010
- Containment of Bioaerosol Infection Risk by the Xpert MTB/RIF Assay and Its Applicability to Point-of-Care SettingsJournal of Clinical Microbiology, 2010
- Tuberculosis Diagnosis — Time for a Game ChangeThe New England Journal of Medicine, 2010